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Figure 2. Patient Outcomes.
Table
Leiden Utrecht Total
Number of patients (n) 142 109 251
Male sex [n (%)] 96 (68) 61 (56) 157 (63)
Age (years) 6á2 (0á4-19) 5á9 (0á2-23) 6á2 (0á2-23)
Cumulative Thymoglobulin
dose [n (%)]
<9 mg/kg 4 (3) 5 (5) 9 (4)
9-11 mg/kg 136 (96) 97 (89) 233 (92)
>11 mg/kg 2 (1) 7 (6) 9 (4)
Diagnosis [n (%)]
Malignancy 69 (49) 47 (43) 116 (46)
Abstracts / Biol Blood Marrow Transplant 21 (2015) S79eS107 S91R-ATG (2mg/kg/d x4d), and TLI (500cGy) followed by FHI TCD
AlloSCT. We utilize the CliniMACS System (IND 14359) to
enrich for peripheral blood hematopoietic progenitor cells
with a target dose of 10 x 106 CD34+ cells/kg and 2 x 105
CD3+ T cells/kg added back as a ﬁnal CD3/kg concentration.
Results: Seven patients have received AlloSCTs from
maternal donors. Neutrophil engraftment has been rapid
(median 9d; range, 9-13d) and none has developed GVHD.
All patients have achieved94% whole blood chimerism and
CD71 (erythroid) chimerism (Fig. 2). Six evaluable patients
achieved full donor (95%) peripheral blood chimerism by
day 60, and 3 of 6 achieved full donor CD3 chimerism in
that time (Fig. 2). Absolute CD4 counts of 200/mm3 have
been achieved in all patients 270 days post-transplant.
There have been no serious bacterial infections and only 1
viral infection. Six of 7 patients are alive and free of disease
(day +24 to +710) with 1 death of VOD at day +59.
Early results indicate FHI TCD AlloSCT is feasible and well
tolerated inhigh-risk SCDpatients. A larger cohort is needed to
assess long-term safety and outcomes. (Supported by grants
from the FDA [5R01FD004090] and Otsuka and CliniMACS
supplies from Miltenyi Biotec) (IND#14359; NCT01461837;
http://www.sicklecelltransplantconsortium.org)Immune deﬁciency 23 (16) 28 (26) 51 (20)
Bone marrow failure 6 (4) 9 (8) 15 (6)
Benign disorders 44 (31) 25 (23) 69 (28)
Stem cell source [n (%)]
Bone marrow 89 (63) 29 (27) 118 (47)
Peripheral blood stem cells 30 (21) 12 (11) 42 (17)
Cordblood 23 (16) 68 (62) 91 (37)
Conditioning regimen
[n (%)]
Reduced intensity 0 (0) 6 (5) 6 (2)
Chemotherapy-based 103 (73) 88 (81) 191 (76)
TBI-based 39 (27) 15 (14) 54 (22)
Positive CMV status of
recipient [n (%)]
70 (49) 56 (51) 126 (50)
Positive CMV status of
donor [n (%)]
57 (40) 19 (17) 76 (30)
Follow up (weeks) 126 (3-427) 84 (1-382) 111 (1-427)
Shown as median (range)
unless otherwise
speciﬁed
Thymoglobulin exposure is a predictor for IR, GvHD and GF, and in sub-
groups for OS. IR is a predictor for OS and EFS. Individualized dosing of
Thymoglobulin targeting to optimal Thymoglobulin exposures may
improve the outcomes after (pediatric) HCT.88
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Leiden, NetherlandsThymoglobulin is introduced to the conditioning regimen in
hematopoietic cell transplantation (HCT) to prevent graft-
versus-host-disease (GvHD) and graft failure (GF). Side
effects of Thymoglobulin include delayed immune reconsti-
tution (IR) of donor T-cells. We determine the therapeutic
window by studying the relationship between Thymoglo-
bulin exposure and clinical outcome.
All ﬁrst HCT’s in pediatric patients between 2004-2012
receiving Thymoglobulin in the two Dutch pediatric HCT cen-
ters were included. Thymoglobulin exposure measures were
determined using a validated population pharmacokinetic
Figure 1. Panel A: Post-HCT AUC of active Thymoglobulin of patients with an unsuccessful or successful CD4+ T-cell reconstitution at day +100(0) and patients with
acute GvHD grade 2-4 (I) with a logistic regression depicting the chance of successful reconstitution versus post-HCT AUC (solid line) and the chance of developing
aGvHD grade 2-4 versus post-HCT AUC (dot-dashed line). Dashed line: 50% chance of event. Panel B: Kaplan Meier survival curve of overall survival according to
successful CD4+ immune reconstitution.
Figure 2. OS according to post-HCT AUC in CB recipients with benign disease (panel A) and matched BM/PBSC recipients (panel B).
Figure 3. Acute GvHD (panel A), Chronic GvHD (panel B) and graft failure (panel C) according to pre-HCT Thymoglobulin AUC.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S79eS107S92model. Primary endpoint was IR (deﬁned as CD4+ T-cells
>50106/L in two consecutive measurements within 100
days); secondary endpoints were overall survival (OS), event-
free survival, acute and chronic GvHDandGF. Cox proportional
hazard and logistic regression models were used.
In a cohort of 251 patients (Table 1), low post-HCT area
under the curve (AUC) of active Thymoglobulin was
the best predictor for successful IR (P<0.0001; Fig 1a).
Incidence of GvHD was not signiﬁcantly inﬂuenced by
post-HCT AUC. Successful IR is associated with OS inmultivariate analyses (MV) (HR 0.49, P¼0.005; Fig 1b)
through reducing relapse and non-relapse mortality. Sub-
group analyses showed a direct association between post-
HCT AUC and OS in cord blood recipients with a benign
disease (< > 20 AU*day/mL) and matched bone marrow/
PBSC sources (< > 50 AU*day/mL) (Fig 2). Incidence of
acute grade 2-4 and chronic GvHD and GF was most
inﬂuenced by pre-HCT Thymoglobulin exposure in all pa-
tients (< > median of 40 AU*day/mL; P<0.01, P¼0.03 and
P¼0.03 in MV, respectively; Fig 3).
